Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: Correlation of hormonal data with clinical responses

R. J. Santen, T. J. Worgul, E. Samojlik, A. E. Boucher, Allan Lipton, Harold Harvey

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Human breast neoplasms can be divided into hormone-dependent and hormone-independent subtypes. Estrogen is the major hormonal stimulus for growth of the dependent tumors. Failure to respond to estrogen suppression therapy could reflect either an incomplete lowering of estrogens or the hormonal independence of the tumor. To address this issue, we compared the levels of several estrogens and other hormones in women experiencing objective responses (the responders) and disease progression (the progression group) during therapy with the aromatase-steroidogenesis inhibitor, aminoglutethimide, and replacement hydrocortisone. Pretreatment hormonal profiles of the estrogens, androgens, ketosteroids, thyroxine, polypeptide hormones, and carcinoembryonic antigen treatment, the levels of all estrogens were suppressed to a similar degree in the progression group and in the responders. Urinary estrone, for example, fell to 16.7 ± 3.2% of basal in the responders versus 16.3 ± 3.8% of basal in the progression group. These data suggested the lack of estrogen suppression did not explain the response to treatment in the patients receiving aminoglutethimide-hydrocortisone. This finding differs from our results in a similarly analyzed control group of patients treated with surgical adrenalectomy. Levels of the weak androgens, dehydroepiandrosterone sulfate and androstenedione, were found to be higher in the progression group compared to the responders. This observation could not be explained by differences in duration of treatment between groups. Analysis at 1 to 12 weeks, 13 to 24 weeks, and 25 to 36 weeks after initiating treatment indicated higher androgen levels at each time point in the progression group. In addition, the results were not attributable to differing serum levels of aminoglutethimide among responder groups. While the finding of higher androgen levels in the responder group remains unexplained, this study indicates that incomplete estrogen suppression is not responsible for lack of tumor response in patients with progressive disease during aminoglutethimide-hydrocortisone therapy.

Original languageEnglish (US)
Pages (from-to)3397s-3401s
JournalCancer Research
Volume42
Issue number8 Suppl.
StatePublished - 1982

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: Correlation of hormonal data with clinical responses'. Together they form a unique fingerprint.

Cite this